Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A vaccine study involving healthy adults

You are invited to take part in a study investigating a new vaccine against Respiratory Syncytial Virus (RSV).  The study is being run by the Oxford Vaccine Group which is part of the University of Oxford.

Please get in touch if you:

·      are aged 18 to 45 years old and in good health

·      are able to attend visits at the Churchill Hospital, Oxford

·      are interested in preventing a major cause of global infant deaths


We will provide reimbursement for your time, inconvenience and travel. The total study participation time is 1 year.


Before you decide whether you would like to take part, it is important for you to understand exactly what the study is about and what participation would involve.  If you would like to read more about the study and see if you are you eligible to take part, please go to here.


If you would like to discuss the study further, please contact us:

Telephone: 01865 857420

Email: info@ovg.ox.ac.uk

Similar stories

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

Oral paratyphoid vaccine to begin human trials

The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.

Oxford scientist named Australian of the Year in the UK

The Oxford Vaccine Group’s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.

Angelman syndrome: first patient to receive potential therapy in Oxford

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.

Why it's so hard to treat pain in infants

For decades physicians believed that premature babies didn’t experience pain. Here’s what doctors know now – and the innovative solutions being embraced by today's caregivers.